Valuation: HighTide Therapeutics, Inc.

Market Cap 1.46B 1.71B 218M 195M 181M 165M 310M 20.69B 316M 2.18B 852M 10.79B 820M 802M 34.54B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.09B 1.27B 162M 145M 135M 122M 230M 15.37B 235M 1.62B 633M 8.02B 609M 596M 25.66B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 day-2.91%
1 week-13.79%
Current month-12.66%
1 month-9.91%
3 months+17.65%
6 months-16.20%
Current year+1.69%
1 week 3
Extreme 3
3.51
1 month 3
Extreme 3
3.66
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Director/Board Member 68 30/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap. Importance
30/4/26 Other

Director

1,800,000 0.3151%
1/4/26 Other

Chief Executive Officer

8,325,618 1.4572%
1/4/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%-13.79%-9.37% - 225M
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%+7.51%+8.12%+61.40% 51.9B
+3.14%+7.17%+12.48%+41.70% 48.73B
+3.29%+4.20%+32.80%+35.57% 43.13B
-1.59%+1.15%+283.96%+457.71% 41.48B
+5.99%+6.26%+17.68%+113.90% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.89%-1.97%-13.50%-6.93% 22.27B
Average +1.04%-4.63%+44.63%+90.98% 37.32B
Weighted average by Cap. +1.54%-3.50%+54.32%+97.61%

Financials

2024 2025
Net sales - -
Net income -382M -448M -57.04M -50.91M -47.32M -43.04M -80.98M -5.4B -82.44M -568M -222M -2.82B -214M -210M -9.02B -245M -287M -36.6M -32.67M -30.36M -27.62M -51.96M -3.47B -52.9M -365M -143M -1.81B -137M -134M -5.79B
Net Debt -413M -484M -61.67M -55.05M -51.16M -46.54M -87.56M -5.84B -89.14M -615M -240M -3.05B -231M -227M -9.75B -376M -441M -56.17M -50.14M -46.6M -42.39M -79.75M -5.32B -81.18M -560M -219M -2.78B -211M -206M -8.88B
Projected Income Statement - Annual - HighTide Therapeutics, Inc.
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
55
Date Price Change Volume
15/10/26 HKD 3.000 -2.91% 68,000
14/10/26 HKD 3.090 -0.96% 220,500
13/10/26 HKD 3.120 -2.35% 631,000
12/10/26 HKD 3.195 -6.72% 325,500
09/10/26 HKD 3.425 +1.93% 2,917,500

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - HighTide Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. 2511 Stock